Investigative Ophthalmology & Visual Science Cover Image for Volume 59, Issue 9
July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Aflibercept versus bevacizumab and/or ranibizumab for recurrent macular edema secondary to central retinal vein occlusion
Vaidehi Dedania; Cem Ozgonul; Cagri G Besirli
Author Affiliations & Notes
  • Vaidehi Dedania
    Ophthalmology and Visual Sciences, Kellogg Eye Center/University of Michigan, New York, New York, United States
  • Cem Ozgonul
    Ophthalmology and Visual Sciences, Kellogg Eye Center/University of Michigan, New York, New York, United States
  • Cagri G Besirli
    Ophthalmology and Visual Sciences, Kellogg Eye Center/University of Michigan, New York, New York, United States
  • Footnotes
    Commercial Relationships   Vaidehi Dedania, None; Cem Ozgonul, None; Cagri Besirli, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4287. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Aflibercept versus bevacizumab and/or ranibizumab for recurrent macular edema secondary to central retinal vein occlusion
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Vaidehi Dedania, Cem Ozgonul, Cagri G Besirli; Aflibercept versus bevacizumab and/or ranibizumab for recurrent macular edema secondary to central retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4287.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : To compare functional and anatomic outcomes of treatment with intravitreal aflibercept versus bevacizumab and/or ranibizumab in patients with recurrent macular edema (ME) secondary to central retinal vein occlusion (CRVO).

Methods : Retrospective, comparative case series of patients with recurrent ME in the setting of CRVO. Patients with recurrent ME received treatment with aflibercept (Group 1, G1) or bevacizumab and/or ranibizumab (Group 2, G2). Primary outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT).

Results : Of the 20 eyes (20 patients) with recurrent ME included in the study, 9 received aflibercept (G1) and 11 received bevacizumab and/or ranibizumab (G2). Median BCVA at recurrence of ME and at most recent follow-up was 20/60 (G1) and 20/80 (G2) and 20/40 (G1) and 20/50 (G2, p> 0.05 for all comparisons), respectively. Median CFT at recurrence of ME and at most recent follow-up was 492 μm (G1) and 448 μm (G2) and 291 μm (G1) and 295 μm (G2, p> 0.05 for all comparisons), respectively. Complete resolution of ME for at least 4 months was found in 78% (G1) and 55% (G2) of patients with a median injection free interval of 11 (G1) and 13 (G2) months (p> 0.05).

Conclusions : In patients with recurrent ME secondary to CRVO, there was improvement in BCVA and CFT in all groups, although patients treated with aflibercept showed a trend toward better anatomical outcomes decreased need for recurrent injections.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) in Groups 1 and 2.* (A) There was a decline in BCVA in both groups at the time of recurrence, but improvement after treatment with aflibercept (Group 1) or bevacizumab and/or ranibizumab (Group 2). (B) CFT increased at the time of recurrence of macular edema and decreased after treatment with aflibercept (Group 1) and bevacizumab and/or ranibizumab (Group 2).
View OriginalDownload Slide

Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) in Groups 1 and 2.* (A) There was a decline in BCVA in both groups at the time of recurrence, but improvement after treatment with aflibercept (Group 1) or bevacizumab and/or ranibizumab (Group 2). (B) CFT increased at the time of recurrence of macular edema and decreased after treatment with aflibercept (Group 1) and bevacizumab and/or ranibizumab (Group 2).

Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) in Groups 1 and 2.* (A) There was a decline in BCVA in both groups at the time of recurrence, but improvement after treatment with aflibercept (Group 1) or bevacizumab and/or ranibizumab (Group 2). (B) CFT increased at the time of recurrence of macular edema and decreased after treatment with aflibercept (Group 1) and bevacizumab and/or ranibizumab (Group 2).

Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) in Groups 1 and 2.* (A) There was a decline in BCVA in both groups at the time of recurrence, but improvement after treatment with aflibercept (Group 1) or bevacizumab and/or ranibizumab (Group 2). (B) CFT increased at the time of recurrence of macular edema and decreased after treatment with aflibercept (Group 1) and bevacizumab and/or ranibizumab (Group 2).
View OriginalDownload Slide
 
Figure 2. Spectral-domain optical coherence tomography of a patient in Group 1. A 72-year-old man with (A) complete resolution of macular edema (ME) after 3 injections of bevacizumab (BCVA 20/30, CFT = 297 μm), (B) recurrence of ME after 6 months (BCVA 20/50, CFT = 551 μm) and (C) complete resolution of ME after 4 monthly injections of aflibercept without recurrence 21 months after the last aflibercept injection (BCVA 20/25, CFT = 289 μm).
View OriginalDownload Slide

Figure 2. Spectral-domain optical coherence tomography of a patient in Group 1. A 72-year-old man with (A) complete resolution of macular edema (ME) after 3 injections of bevacizumab (BCVA 20/30, CFT = 297 μm), (B) recurrence of ME after 6 months (BCVA 20/50, CFT = 551 μm) and (C) complete resolution of ME after 4 monthly injections of aflibercept without recurrence 21 months after the last aflibercept injection (BCVA 20/25, CFT = 289 μm).

Figure 2. Spectral-domain optical coherence tomography of a patient in Group 1. A 72-year-old man with (A) complete resolution of macular edema (ME) after 3 injections of bevacizumab (BCVA 20/30, CFT = 297 μm), (B) recurrence of ME after 6 months (BCVA 20/50, CFT = 551 μm) and (C) complete resolution of ME after 4 monthly injections of aflibercept without recurrence 21 months after the last aflibercept injection (BCVA 20/25, CFT = 289 μm).

Figure 2. Spectral-domain optical coherence tomography of a patient in Group 1. A 72-year-old man with (A) complete resolution of macular edema (ME) after 3 injections of bevacizumab (BCVA 20/30, CFT = 297 μm), (B) recurrence of ME after 6 months (BCVA 20/50, CFT = 551 μm) and (C) complete resolution of ME after 4 monthly injections of aflibercept without recurrence 21 months after the last aflibercept injection (BCVA 20/25, CFT = 289 μm).
View OriginalDownload Slide

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept